Chào mừng trở lại
Tham gia Cointime
Đăng nhập với email
Đăng nhập với
Đăng ký
Duality Biologics
About
Duality Biologics is a company focusing on the discovery, development and commercialization of new modality biologics to provide solutions.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $90M
- Industries
- Biopharma,Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2020
- Number Of Employee
- 11 - 50
- Operating Status
- Active
“To Translate Novel Modality into Reality”. Duality Biologics was founded in January 2020 by Dr. John Zhu, a well-respected investor in the healthcare industry. Duality Bio is committed to developing novel modality drugs to fulfill the unmet medical needs for patients worldwide. Focusing on the oncology and autoimmune diseases, the company has built a novel internal pipeline including nearly 10 Best-in-Class and First-in-Class bispecific antibody and Antibody-Drug Conjugate (ADC) drugs, of which several drug candidates are in the IND stage. The company has successfully built the next-generation ADC platform with global intellectual property rights. The value of this platform has been validated by a number of drug candidates under development.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 19, 2021 | Series B | $90M | 1 |
Lilly Asia Ventures
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Lilly Asia Ventures
|
Yes | Series B |
